Resiquimod (R-848)

Resiquimod (CAS 144875-48-9) is an orally bioavailable imidazoquinoline compound that acts as a potent agonist of Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8) in immune cells, inducing strong immune stimulatory responses in a variety of cell types. In addition, resiquimod modulates innate immune responses by inducing the production of key cytokines (such as TNF-alpha, IL-6, and IFN-alpha) and promotes the activation and maturation of dendritic cells.

In experimental studies, resiquimod significantly enhances the secretion of pro-inflammatory and antiviral cytokines, an activity verified in human peripheral blood mononuclear cells (PBMCs), mouse splenocytes, and other immune-related cell lines. It also induces upregulation of co-stimulatory molecules and promotes antigen presentation by immune cells, thereby enhancing the overall immune response against pathogens or tumor antigens.

In immunology and translational medicine research, resiquimod is widely used to activate innate immune pathways, study TLR-mediated signal transduction, and serve as a tool compound in the development of immunomodulatory therapies. Resiquimod potently promotes cytokine production and is commonly used in preclinical studies of infectious diseases, tumor immunotherapy, and vaccine adjuvant development.

Resiquimod is commonly used to establish models such as autoimmune disease models; local administration induces skin immune responses and is widely used for immunomodulatory drug evaluation.